Get the Stockscreener App
45.12
1.66%
-0.76
Disc Medicine Inc stock is traded at $45.12, with a volume of 274.28K.
It is down -1.66% in the last 24 hours and down -2.25% over the past month.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.
See More
Previous Close:
$45.88
Open:
$45.73
24h Volume:
274.28K
Relative Volume:
0.66
Market Cap:
$1.56B
Revenue:
-
Net Income/Loss:
$-91.00M
P/E Ratio:
-12.29
EPS:
-3.67
Net Cash Flow:
$-74.38M
1W Performance:
-7.71%
1M Performance:
-2.25%
6M Performance:
-30.10%
1Y Performance:
+30.18%
1-Day Range:
$44.85
$47.25
1-Week Range:
$44.85
$49.93
52-Week Range:
$30.82
$68.73
Disc Medicine Inc Stock (IRON) Company Profile
Name
Disc Medicine Inc
Sector
Industry
Phone
(617) 674-9274
Address
321 ARSENAL STREET, SUITE 101, WATERTOWN
Compare IRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
45.12 | 1.69B | 0 | -91.00M | -74.38M | -3.67 |
|
ONC
Beigene Ltd Adr
|
240.41 | 25.57B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.10 | 111.79B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 39.90M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.85 | 65.28B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.93 | 6.31B | 0 | -153.72M | -103.81M | -2.00 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Nov-05-24 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-04-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-23-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Aug-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-01-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-19-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-09-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Jun-07-23 | Initiated | H.C. Wainwright | Buy |
| May-17-23 | Initiated | Raymond James | Outperform |
| Apr-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-21-23 | Initiated | Stifel | Buy |
| Apr-20-23 | Initiated | Morgan Stanley | Overweight |
| Mar-23-23 | Initiated | BMO Capital Markets | Outperform |
| Feb-28-23 | Initiated | SVB Securities | Outperform |
View All
Disc Medicine Inc Stock (IRON) Latest News
Disc Medicine to Participate in Upcoming Investor Conferences - GlobeNewswire
Disc Medicine Sets Double Conference Appearance: Jefferies and Goldman Sachs Healthcare Events - Stock Titan
BNP Paribas Financial Markets Invests $324,000 in Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
Disc Medicine, Inc. (NASDAQ:IRON) Stock Position Raised by Deutsche Bank AG - Defense World
Insider Sell: William Savage Sells Shares of Disc Medicine Inc (IRON) - GuruFocus
Disc Medicine’s chief medical officer sells $334,128 in stock By Investing.com - Investing.com Canada
Disc Medicine’s chief medical officer sells $334,128 in stock - Investing.com
Porphyria Pipeline 2025: Groundbreaking Clinical - openPR.com
Disc Medicine, Inc. (NASDAQ:IRON) Shares Purchased by Northern Trust Corp - Defense World
Commit To Buy Disc Medicine At $35, Earn 14.1% Annualized Using Options - Nasdaq
Disc Medicine Announces Multiple Presentations Across Portfolio - GuruFocus
Disc Medicine, Inc. to Present Key Data from Hematology Portfolio at EHA 2025 Congress - Nasdaq
Disc Medicine Announces Multiple Presentations Across - GlobeNewswire
Disc Medicine Reveals First Disease-Modifying EPP Treatment Data Among 6 Clinical Updates at EHA 2025 - Stock Titan
BMO Capital Markets Forecasts Strong Price Appreciation for Disc Medicine (NASDAQ:IRON) Stock - Defense World
Disc Medicine to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference - The Manila Times
Tower Research Capital LLC TRC Increases Stake in Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
How To Trade (IRON) - news.stocktradersdaily.com
Disc Medicine (IRON) Price Target Raised by BMO Capital | IRON S - GuruFocus
Promising Outlook for Disc Medicine’s DISC-0974 in Anemia Treatment Justifies Buy Rating - TipRanks
BMO Capital Boosts Price Target for Disc Medicine (IRON) to $120 - GuruFocus
Cantor Fitzgerald Comments on Disc Medicine FY2025 Earnings - Defense World
Q2 EPS Estimates for Disc Medicine Cut by Leerink Partnrs - Defense World
Insider Sellers Might Regret Selling Disc Medicine Shares at a Lower Price Than Current Market Value - simplywall.st
Disc Medicine, Inc. (NASDAQ:IRON) Shares Acquired by Dimensional Fund Advisors LP - Defense World
Wedbush Issues Negative Forecast for Disc Medicine Earnings - Defense World
Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Disc Medicine Reports Strong Q1 2025 Progress - TipRanks
Here's Why We're Not Too Worried About Disc Medicine's (NASDAQ:IRON) Cash Burn Situation - Yahoo Finance
Decoding Disc Medicine Inc (IRON): A Strategic SWOT Insight - GuruFocus
Market Resilience: Disc Medicine Inc (IRON) Finishes Weak at 42.58, Down -12.40 - DWinneX
Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Disc Medicine reports Q1 EPS ($1.02), consensus ($1.07) - TipRanks
Disc Medicine, Inc. SEC 10-Q Report - TradingView
Disc Medicine Inc (IRON) Reports Q1 2025 EPS of -$1.02, Aligns with Estimates; Strong Cash Position of $694.7 Million - GuruFocus
Disc's Bitopertin Program Advances with APOLLO Trial Launch | IRON Stock News - GuruFocus
Disc Medicine, Inc. Reports Q1 2025 Financial Results and Updates on Bitopertin and Pipeline Programs - Nasdaq
Invesco Ltd. Increases Stock Holdings in Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
(IRON) On The My Stocks Page - news.stocktradersdaily.com
Wells Fargo & Company MN Grows Position in Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
Disc Medicine to Host Webinar with Key Opinion Leaders on Anemia of Myelofibrosis (MF) - The Manila Times
Leading Cancer Centers Join Forces to Review Breakthrough Myelofibrosis Anemia Treatment Data - Stock Titan
JPMorgan Chase & Co. Purchases 44,762 Shares of Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
Renaissance Technologies LLC Makes New $5.48 Million Investment in Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
When (IRON) Moves Investors should Listen - news.stocktradersdaily.com
Disc Medicine, Inc. (NASDAQ:IRON) Shares Sold by Geode Capital Management LLC - Defense World
New GlyT-1 inhibitors disclosed in Disc Medicine patent - BioWorld MedTech
Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Rating of “Buy” by Brokerages - Defense World
Disc Medicine price target raised to $132 from $99 at Cantor Fitzgerald - MSN
Vanguard Group Inc. Has $67.73 Million Stock Holdings in Disc Medicine, Inc. (NASDAQ:IRON) - Defense World
Disc Medicine Inc Stock (IRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
8.70%
1.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):